Axiodis CRO
Axiodis SAS — a specialist French clinical CRO acquired by Oxurion (72% stake). Experts in clinical biometrics, data management, biostatistics, regulatory submissions and the proprietary Exagis CDMS platform.
oxurion.comCrawled Nov 21, 2026
Axiodis SAS — a specialist French clinical CRO acquired by Oxurion (72% stake). Experts in clinical biometrics, data management, biostatistics, regulatory submissions and the proprietary Exagis CDMS platform.
Exagis is Axiodis's proprietary next-generation eCRF and clinical data management platform. HDS-certified, CDISC-native (CDASH/SDTM), 11 languages, standard setup in 5 business days. Built by biostatisticians for biometrics-heavy clinical trials.
Insights from Axiodis on clinical data management, biometrics, regulatory compliance, and the Exagis eCRF platform. Articles for data managers, biostatisticians, sponsors and clinical operations teams.
Regulated information — 2026-10-14 — Oxurion NV (Euronext Brussels: OXUR)
Regulated information — 2026-10-28 — Oxurion NV (Euronext Brussels: OXUR)
Regulated information — 2026-11-06 — Oxurion NV (Euronext Brussels: OXUR)
Regulated information — 2026-11-18 — Oxurion NV (Euronext Brussels: OXUR)
Regulated information — 2026-10-12 — Oxurion NV (Euronext Brussels: OXUR)
All regulated press releases and financial disclosures by Oxurion NV (Euronext Brussels: OXUR). Includes regulated information under Belgian FSMA rules, inside information, and corporate announcements.
About Oxurion NV — executive team, board of directors, and corporate overview. Oxurion is a Belgian company (Euronext Brussels: OXUR) building Europe's leading group of contract research organisations.
Contact Oxurion NV — general enquiries, investor relations, and media contacts. Headquartered in Belgium, listed on Euronext Brussels (OXUR).
Investor relations for Oxurion NV (Euronext Brussels: OXUR). Financial filings, regulated press releases, shareholder information, corporate governance, and investor contact.
Oxurion (Euronext Brussels: OXUR) is a Belgian company building a leading European group of contract research organisations through buy-and-build acquisitions.